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Background & Aims: Micro-RNA (miRNA) are endoge-
nous regulatory RNA molecules that modulate gene
expression. Alterations in miRNA expression can contrib-
ute to tumor growth by modulating the functional ex-
pression of critical genes involved in tumor cell prolifer-
ation or survival. Our aims were to identify speciﬁc
miRNA involved in the regulation of cholangiocarcinoma
growth and response to chemotherapy. Methods: miRNA
expression in malignant and nonmalignant human
cholangiocytes was assessed using a microarray. Ex-
pression of selected miRNA and their precursors was
evaluated by Northern blots and real-time polymerase
chain reaction, respectively. The effect of selected
miRNA on cell growth and response to chemotherapy
was assessed using miRNA-speciﬁc antisense oligonu-
cleotides to decrease miRNA expression or with precur-
sor miRNA to increase cellular expression. Results:
miRNA expression was markedly different in malignant
cholangiocytes, with decreased expression of many
miRNA compared with nonmalignant cells. A cluster of
miRNA, including miR-320, miR-200b, miR-21, miR-
23a, miR-141, miR-27a, and miR-34a, were expressed
in all cell lines. MiR-21, miR-141, and miR-200b were
highly over-expressed in malignant cholangiocytes. Inhibi-
tion of miR-21 and miR-200b increased sensitivity to gem-
citabine, whereas inhibition of miR-141 decreased cell
growth. Treatment of tumor cell xenografts with systemic
gemcitabine altered the expression of a signiﬁcant number
of miRNA. miR-21 modulates gemcitabine-induced apo-
ptosis by phosphatase and tensin homolog deleted on
chromosome 10 (PTEN)-dependent activation of PI 3-ki-
nase signaling. Potential target genes that were modu-
lated by selected miRNA were identiﬁed. Conclusions: Al-
terations in miRNA expression contribute to tumor growth
and response to chemotherapy. Aberrantly expressed
miRNA or their targets will provide mechanistic insight and
therapeutic targets for cholangiocarcinoma.
Micro-RNA (miRNA) are a group of endogenoussmall, noncoding RNA that can modulate protein
expression by regulating translational efﬁciency or cleav-
age of target mRNA. Although several hundred miRNA
have been cloned or predicted, a functional role for these
in many cellular processes has not been fully elucidated.1
The best characterized role of miRNA has been as a
developmental regulator in Caenorhabditis elegans and
Drosophilia. More recently, several other roles have been
described including regulation of apoptosis and differen-
tiation. miRNA are expressed as long precursor RNA
that are processed by a single nuclease Drosha prior to
transport into the cytoplasm by an exportin-5-dependent
mechanism. In the cytoplasm, miRNA are further
cleaved by Dicer. The result is a 17–24 nucleotide (nt)
small miRNA that can complex with sequence comple-
mentary in a manner similar to the RNA-induced silenc-
ing complex, which is also formed during the RNA
interference process. The miRNA are then targeted to
sequences that are at least partially complementary to the
miRNA. The translation of the bound mRNA is then
inhibited or the mRNA transcript degraded based on the
sequence match. Although the targets of miRNA have
not been fully characterized, potential targets can be
predicted based on sequence complementarity.
A role for miRNA in cancer is emerging with the
recent identiﬁcation that miRNA may be important
contributors to cancer development. Studies of miRNA
expression proﬁles in cancer samples have identiﬁed a
handful of miRNA that are differentially regulated in
tumors, suggesting a possible link between miRNA and
oncogenesis.2,3 miRNA targets can include genes in-
volved in differentiation or transformation, such as tran-
scription factors and cell-cycle control. Tumorigenesis
might result from the perturbation of these pathways by
mutations in the miRNA genes, their 3=-untranslated
region (UTR) miRNA-binding sites, or in pathways that
regulate their expression. Through modulation of cell
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differentiation and proliferation, miRNA can control and
regulate many cellular processes germane to tumor gen-
esis, growth, and survival. Many miRNA genes are lo-
cated at chromosomal fragile sites or regions of cytoge-
netic abnormalities associated with cancer.4 Moreover,
the pattern of expression of miRNA has been shown to
deﬁne accurately the speciﬁc cancer types.5 However, the
biologic consequences of alterations in miRNA expres-
sion in cancer cells remain undeﬁned.
Cholangiocarcinomas are enigmatic malignancies of the
biliary tract that are highly chemoresistant.6–8 The need for
improved treatments for this cancer is highlighted by the
dramatic increases in the incidence of cholangiocarcinoma
in several regions of the world.9–11 The mechanisms regu-
lating cholangiocarcinoma growth and resistance to chemo-
therapy are poorly understood. Although miRNA are be-
coming increasingly recognized as regulatory molecules in
human cancers, their involvement in functional responses to
environmental changes such as exposure to chemotherapy is
unknown. We postulated that aberrant expression of
miRNA in cancer cells could modulate the functional ex-
pression of critical genes involved in tumor cell behavior,
such as genes contributing to cell survival in response to
chemotherapeutic stress. Our aims were, thus, to identify
the miRNA that were differentially expressed in malignant
human cholangiocytes and to recognize speciﬁc miRNA
involved in the regulation of tumor cell growth and re-
sponse to chemotherapy. We asked the following questions:
Are miRNA differentially activated in malignant cholan-
giocytes? If so, does their expression reﬂect cytogenetic
abnormalities? Can aberrantly expressed miRNA regulate
tumor cell growth or survival? Are miRNA involved in
chemotherapeutic responses in cholangiocarcinoma?
Materials and Methods
Cell Lines and Cultures
The KMCH-1, Mz-ChA-1, and TFK human cholan-
giocarcinoma cell lines and the nonmalignant human cholan-
giocyte H69 cell lines were obtained as previously de-
scribed.12–14 Mz-ChA-1 cells are derived from metastatic
gallbladder cancer, TFK-1 cells from common bile duct can-
cer, and KMCH from an intrahepatic mixed cholangiocellular-
hepatocellular carcinoma. H69 cells are derived from nonma-
lignant cholangiocytes and immortalized by SV40
transfection.15 KMCH and Mz-ChA-1 cells were cultured in
CMRL 1066 media with 10% fetal bovine serum (FBS), 1%
L-glutamine, and 1% antimycotic antibiotic mix. H69,
KMCH, and TFK cells were cultured in Dulbecco’s modiﬁed
Eagle medium (DMEM)/F-12 and minimum essential media
(MEM) as previously described.12 Normal human intrahepatic
biliary epithelial cells and epithelial cell medium used for their
growth were obtained from ScienCell research laboratories (San
Diego, CA). All other cell culture media and supplements were
obtained from Invitrogen (Carlsbad, CA).
Transfections
Transfections were performed by electroporation using
the Nucleofector system (Amaxa Biosystems, Koln, Germany).
Transfection conditions for each cell type were ﬁrst optimized
to result in 20%–30% transfection efﬁciency with viability
80%. All studies were performed in quadruplicate. Cells
(1–2  106) were spun down at 1000 rpm for 5 minutes, and
the medium was removed. Cells were then resuspended in 100
L Nucleofector solution (Amaxa Biosystems) at room tem-
perature followed by addition of 20 L of 100 nmol/L mi-
croRNA precursor, antisense inhibitor, or controls (all ob-
tained from Ambion Inc., Austin, TX). Electroporation was
performed using the Nucleofector (Amaxa Biosystems). Trans-
fected cells were then resuspended in regular culture media
containing 10% serum for 48–72 hours prior to study.
Isolation of miRNA
Total RNA from cell lines and tumor tissue samples
were isolated using the Totally RNA isolation kit (Ambion).
The miRNA fraction was obtained by mixing RNA with 2X
sample buffer and ﬂashPAGE puriﬁcation using ﬂashPAGE
precast Gels and the ﬂashPAGE Fractionator System (Am-
bion). The size of the miRNA fractions were conﬁrmed using
an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Palo
Alto, CA).
miRNA Array Hybridization and Analysis
The isolated miRNA from the pooled sample were
appended 3= amine-modiﬁed tails using the mirVana miRNA
Array Labeling Kit (Ambion) and then ﬂuorescently coupled
with Cy3 or Cy5 using the Post Labeling Reactive Dye kit
(Amersham Bioscience, Pittsburgh, PA). The Cy3 (control)
and Cy5 (treated) labeled samples were washed 3 times using
miRNA washing buffer, mixed in the same labeling cartridge,
eluted, and stored at 70°C or analyzed by hybridizing to
miRNA arrays. miRNA arrays were generated on glass slides
using the mirVana miRNA Array Probe Set (Ambion) and an
OmniGrid Microarrayer (Gene Machines, San Carlos, CA).
Each probe was printed in duplicate. Following hybridization,
the miRNA arrays were scanned using a GenePix 4000A array
scanner (Axon Instruments, Union City, CA). Raw data were
normalized and analyzed using GeneSpring 7.0 Software (Sil-
icon Genetics, Redwood City, CA). Normalization was per-
formed by expressing each miRNA replicate relative to a
control miRNA (Ambion) added to each sample, thus allow-
ing comparisons between chips. An average value of the me-
dian intensity of each replicate in 4 groups was generated.
Heat maps were generated using HeatMap Builder version
1.0 (accessed on-line at http://quertermous.stanford.edu/
heatmap.htm) to illustrate the relative differences. The heat
maps are row normalized between samples based on the min-
imum and maximum values for each miRNA and thus pro-
vided a visual representation of relative differences between
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each miRNA in a nonquantitative manner. miRNA expression
levels were clustered using a hierarchical clustering algorithm
and self-organizing tree algorithm clustering performed using
Multiexperiment Viewer Version 3.1 from The Institute for
Genomic Research.16
Real-Time Polymerase Chain Reaction
Assay for miRNA Precursors
Total RNA was extracted from the cultured cells using
Trizol (Invitrogen), and the concentration of total RNA was
quantitated by measuring the absorbance at 260 nm. Expres-
sion of miRNA precursors was assessed using real-time poly-
merase chain reaction (PCR) as previously described.17,18 One
microgram of total RNA was brieﬂy exposed to RNase-free
DNase I and reverse transcribed to cDNA using gene-speciﬁc
primers and Thermoscript, thermostable reverse transcriptase
(Invitrogen) as described.17 Triplicate reverse transcriptions
were performed from the RNA of each cell line; 0.5 L of
dilute cDNA (1:50) and additional PCR reagents from the
SYBR green core reagent kit (Applied Biosystems) were added
to the reaction along with 800 nmol/L of the PCR primers to
each miRNA precursor.18 PCR was performed in duplicate in
the Applied Biosystems 7900HT real-time PCR instrument
equipped with a 384-well reaction block. PCR was performed
for 15 seconds at 95°C and 1 minute at 60°C for 40 cycles
followed by the thermal denaturation protocol. The expression
of each miRNA relative to U6 RNA was determined using the
2-CT method.17 To simplify the presentation of the data, the
relative expression values were multiplied by 105.
Northern Blotting
Northern blotting was performed as previously re-
ported.19 Brieﬂy, total RNA (20 g) was resolved on 15%
polyacrylamide urea gels and transferred to Genescreen Plus
membranes (Perkin Elmer, Boston, MA). Oligonucleotides
complementary to the mature miRNA were end labeled with
-32P adenosine triphosphate (ATP) and T4 kinase. The mem-
branes were incubated with labeled probe (1.5 106 CPM per
mL hybridization buffer) prior to visualization using phos-
phorimaging. Blots were stripped once and reprobed using a
different oligonucleotide.
Cell Proliferation Assay
Cell proliferation was assessed using the CellTiter 96
AQueous One Solution Cell Proliferation Assay kit (Promega,
Madison, WI), which uses a tetrazolium compound as sub-
strate. Following transfection, cells (10,000/well) were plated
in 96-well plates (BD Biosciences, Rockville, MD) and incu-
bated at 37°C, and cell proliferation was assessed after 3 days
as previously described.20
Cytotoxicity Assay
Transfected cells were seeded into 96-well plates
(10,000 viable cells/well) and incubated with gemcitabine or
appropriate diluent controls in a ﬁnal volume of 200 L
medium containing 0.5% FBS. After 48 hours, cell viability
was assessed using a commercially available tetrazolium biore-
duction assay for viable cells, and cytotoxicity was assessed as
previously described.13
Apoptosis Assay
Cells were washed with phosphate-buffered saline
(PBS) and then resuspended in PBS containing 0.1% Triton X
for 10 minutes on ice, prior to resuspension (5000 cells/L) in
4% PBS-buffered paraformaldehyde solution containing 10
g/mL 4=6-diamidino-2-phenylindole (DAPI). Ten microli-
ters of this suspension was placed on a glass slide and covered
with a coverslip. Nuclear morphology was assessed using a
ﬂuorescence microscope (Olympus BH, Tokyo Japan). Apo-
ptotic nuclei were identiﬁed by condensed chromatin or nu-
clear fragmentation. More than 150 cells were counted, and
the percentage of apoptotic nuclei was determined.
Western Blotting
For immunoblot analysis of cells in culture, cells
grown in 100-mm dishes were washed twice with ice-cold PBS
and then lyzed by incubation for 20 minutes in 1 mL of
ice-cold cell lysis buffer (1% Nonidet P-40, 50 mmol/L
HEPES, pH 7.4, 150 mmol/L NaCl, 2 mmol/L EDTA, 2
mmol/L phenylmethylsulfonyl ﬂuoride, 1 mmol/L sodium
vanadate, 1 mmol/L sodium ﬂuoride, and 1X protease inhib-
itor mixture). Modiﬁed cell lysis buffers (without phosphatase
inhibitors sodium vanadate and sodium ﬂuoride) were used for
PTPN12 and Src[P-Tyr418] immunoblots only. For analysis
of xenograft tissue, the tissue was homogenized, and lysates
were obtained. The protein concentrations of the lysates were
measured using a Bradford protein assay kit (Bio-Rad, Her-
cules, CA). Equivalent amounts of protein were resolved and
mixed with 6X SDS-PAGE sample buffer, electrophoresed in
a 4%–20% linear gradient Tris-HCl-ready gel (Bio-Rad), and
transferred to nitrocellulose membranes. The membranes were
blocked with 5% nonfat dry milk in Tris-buffered saline, pH
7.4, containing 0.05% Tween 20, and were incubated with
primary antibodies and IRDye700 and IRDye800-labelled
secondary antibodies (Rockland, Gilbertsville, PA) according
to the manufacturer’s instructions. The protein of interest was
visualized and quantitated using the LI-COR Odyssey Infrared
Imaging System (LI-COR Bioscience, Lincoln, NE).
Xenograft Model
Eight-week-old male athymic nu/nu mice were ob-
tained from Charles River Laboratories (Wilmington, MA) and
fed food and water ad libitum. The mice were maintained in
accordance with the Institutional Animal Care and Use Com-
mittee (IACUC) procedures and guidelines. They were housed
3 or 4 per cage, and ﬂuorescent light was controlled to provide
alternate light and dark cycles of 12 hours each. Mz-ChA-1
cells (5 106 cells) were suspended in 0.25 mL of extracellular
matrix gel, and the mixture was injected subcutaneously into
the right and left ﬂanks. Xenograft growth was estimated by
serial measurements obtained twice a week. Once xenograft
tumor volume had reached 150 mm3, mice were randomized to
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receive either gemcitabine (120 mg/kg, intraperitoneally [IP])
or control diluent every 3 days for a total of 5 doses. For
analysis of chemotherapy-induced miRNA and protein expres-
sion in vivo, the xenografts were excised, and tissue was
homogenized. An aliquot of the lysates was used for miRNA
isolation as described above and the remainder used for protein
expression studies.
Luciferase Expression Constructs
The pGL3-PTEN-3=-UTR construct, which contains
the putative binding site for mir-21 downstream of the stop
codon in the pGL3 Fireﬂy luciferase reporter, was constructed
as reported.21 Mz-ChA-1 cells were plated (2  106 cells/well)
in 6-well plates. One microgram of pGL3-PTEN-3=-UTR
construct was cotransfected with 1 g of a Renilla luciferase
expression construct pRL-TK (Promega), using Trans-It (Mi-
rus, Madison, WI). Luciferase assays were performed 24 hours
after transfection using the dual Luciferase Reporter Assay
System (Promega).
Reagents
Pre-miR miRNA precursors and Anti-miR miRNA-
speciﬁc inhibitors of miR-141, miR-21, and miR-200b were
purchased from Ambion. Peroxidase-conjugated anti-rabbit
and anti-mouse secondary antibodies were obtained from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA). Antibodies against
circadian locomotor output cycles kaput protein (CLOCK) and
phospho-PI-3 kinase p85 [Tyr508] were from Santa Cruz
Biotechnology Inc; PTEN, phospho-Akt [Ser473], and phos-
pho-mTOR [Ser248] from Cell Signaling, Inc. (Beverly, MA);
PTPN12 from Orbigen, Inc. (San Diego, CA); and phospho-
Src [Tyr418] and -tubulin from Sigma Chemical Co. (St.
Louis, MO). DAPI was obtained from Sigma Chemical Co.,
and 1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-
O-octadecylcarbonate (Akt inhibitor), LY294002, and rapa-
mycin were obtained from Calbiochem (San Diego, CA).
Statistical Analysis
Data are expressed as the mean 	 standard error (SE)
from at least 3 separate experiments performed in triplicate,
unless otherwise noted. The differences between groups were
analyzed using a double-sided Student t test when only 2
groups were present and the null hypothesis was rejected at the
.05 level.
Results
miRNA Are Differentially Expressed in
Human Malignant Cholangiocytes
We began by assessing the expression of miRNA
in several cholangiocyte cell lines (Figure 1A). In each
cell type, there was a wide range of relative miRNA
expression ranging from undetectable to greater than
12-fold that of an internal standard control miRNA. A
list of the miRNA that were expressed at relatively
higher levels than the other miRNA on the array in each
cell line is provided in Table 1. Expression of miR-141
and miR-21 was veriﬁed by Northern blot analysis and
paralleled the expression pattern observed on the
miRNA array (Figure 1C). The level of expression of
miRNA with the highest (miR-21) or lowest (let-7b)
expression for each cell type using the miRNA array
correlated with expression of their respective miRNA
precursors using real-time PCR analysis (Figure 1D).
Although the expression patterns varied with different
cell types, increased expression of several miRNA was
seen in all cell types. These include miR-21, let7a-1,
let7c, let7f-2, miR-320, and miR-16-1. A greater than
5-fold increase in expression was noted for miR-21, and
greater than 5-fold decrease in expression was noted for
let7b, miR-326, miR-351, miR-373, and miR-150 for
all cell types. Because the pattern of miRNA expression
can occur in a tissue-speciﬁc manner, these speciﬁc
miRNA may reﬂect potential markers of a biliary tract
lineage. The pattern of expression for TFK-1 and Mz-
ChA-1 cells was similar to each other and distinct from
KMCH-1 cells, which likely reﬂects differences in their
developmental origins.
Next, we compared miRNA expression between
malignant and nonmalignant cholangiocytes. The pat-
tern of miRNA expression in malignant cells was
markedly different from that of either normal human
intrahepatic biliary tract epithelia or the nonmalig-
nant H69 cells. A heat map showing the relative,
nonquantitative differences between cell lines is
shown in Figure 2. In general, expression of most
miRNA was lower for each of the malignant cells
compared with the nonmalignant cells. For nonmalig-
nant H69 cells, the expression of 22.2% of miRNA
was increased relative to an internal standard control
miRNA (Ambion), greater than for Mz-ChA-1
(6.6%), TFK-1 (14.6%), or KMCH-1 (10.6%) cells.
When the relative expression was compared between
cell lines, expression of a group of miRNA was dif-
ferentially increased in malignant cells (Table 2).
These include the human miR-200b, miR-21, miR-
23a, miR-141, and miR-27a, all of which were ex-
pressed 2.0-fold in Mz-ChA-1 and TFK malignant
cells compared with nonmalignant H69 cells. These
miRNA may play an important role in malignant
transformation or tumor cell behavior. miRNA that
have been reported to be associated with certain can-
cers, such as the miR-17-92 polycistron (B-cell lym-
phoma)22; miR-143 and miR-145 (colon cancer)23;
and miR-15 and miR-16 (chronic lymphocytic leuke-
mia)24 or miR-155 (Burkitt’s lymphoma)25 or miR-
192, miR-194, and miR-215 (various gastrointestinal
2116 MENG ET AL GASTROENTEROLOGY Vol. 130, No. 7
.June 2006 miRNA EXPRESSION IN CHOLANGIOCARCINOMA 2117
tract cancers),5 were not consistently altered in chol-
angiocarcinoma cells. Furthermore, the expression of
several miRNA, such as miR-125a, miR-31, and miR-
95, was decreased in malignant cholangiocytes. These
observations raise the possibility that cholangiocarci-
noma-speciﬁc miRNA expression proﬁles may be use-
ful to develop diagnostic assays. Moreover, the data
suggest that speciﬁc miRNA may be involved in
malignant transformation. These miRNA may con-
tribute to cancer cell behavior through modulating
gene expression either by gene silencing or gene acti-
vation as a result of termination of miRNA-catalyzed
gene silencing.
Correlation Between Genomic Sites of
Human miRNA and Sites of Chromosomal
Gain or Loss in Human
Cholangiocarcinoma
To determine whether the pattern of miRNA
expression reﬂects cytogenetic abnormalities, we corre-
lated the genomic site of miRNA that were differentially
expressed in malignant cells with reported regions of
chromosomal gain or loss in human cholangiocarcinoma.
Of miRNA that were increased in expression, the chro-
mosomal site of miR-141 (12p13.31) was most often
associated with a region of chromosomal gain in biliary
Figure 1. Expression of miRNA in human cholangiocyte cell lines. (A) miRNA was isolated and proﬁling performed as described in the Materials
and Methods section by hybridization to miRNA-speciﬁc probes on epoxy-coated slides. Samples from H69 nonmalignant cholangiocytes were
labeled with Cy3, whereas samples from malignant cholangiocytes were labeled with Cy5. Cluster analysis identiﬁes a group of miRNA that are
increased in expression in malignant cholangiocytes (cluster 1). An enlarged view of this group is shown. (B) Representative spots for selected
miRNA for which expression is differentially increased (miR-21, miR-200b, miR-141), decreased (miR-31, miR-95, miR-125a), or remains
unchanged in malignant cholangiocytes (let7a-1, let 7c, let-7f-2) are illustrated. (C) Northern blotting was performed on the RNA from the cell lines
and probed for miR-21, miR-141, and U6 RNA. The normalized data from the Northern blots (solid bars) and the microarray (open bars) are shown
in the Figure. (D) The expression of miRNA precursors was assessed using real-time PCR and correlated with expression of mature miRNA using
the miRNA array. The relative expression levels for miRNA that were expressed at very high levels on the array (miR-21) or at very low levels
(let-7b) are illustrated by the open bars (n 
 8), whereas relative expression of their respective miRNA precursors by real-time PCR is shown by
the solid bars (n 
 3). Data represent mean 	 standard error.
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tract cancers (3/6 gallbladder cancers, and 1/19 intrahe-
patic cholangiocarcinomas).26,27 However, for most other
differentially expressed miRNA, the miRNA chromo-
somal sites were not associated with reported regions of
chromosomal loss or gain in biliary tract cancers. Am-
pliﬁcation of DNA sequences on chromosomes 2p25.3
and 7q11.23 has been reported in cholangiocarcinoma,
but there are no known miRNA encoded at these
genomic sites.28 Similarly, chromosomal locations of
miRNA that are markedly decreased in expression in
malignant cholangiocytes, such as miR-376b and miR-
215, were not associated with regions of reported chro-
mosomal loss in biliary tract cancers. Unlike other can-
cers such as chronic lymphocytic leukemia or Burkitt’s
lymphoma, altered miRNA expression in cholangiocar-
cinoma does not appear to occur as a result of major
cytogenetic abnormalities.24,25
Regulation of Proliferation by miRNA
miR-141, miR-21, and miR-200b were selected
for further study because they are over expressed in
malignant cholangiocytes, and their genomic locations
exist within regions of reported chromosomal gain in
human cholangiocarcinoma. In Mz-ChA-1 cells, expres-
sion of miR-141 increased by 5.5- 	 0.9-fold, miR-21
increased by 2.7- 	 0.1-fold, and miR-200b increased
by 7.6- 	 0.9-fold relative to nonmalignant cells. The
effects of these 3 miRNA on cell proliferation were
further characterized using speciﬁc antisense oligonucle-
otide miRNA speciﬁc inhibitors. Transfection of Mz-
ChA-1 cells with inhibitors of miR-141, miR-21, and
miR-200b decreased proliferation to 82.3% 	 1.6%,
71.1%	 12.0%, and 77.2%	 5.4%, respectively (all P
 .05), of controls after 72 hours (Figure 3). However,
cell proliferation was not signiﬁcantly altered (93.2% 	
4.6% of controls) by inhibitors to miR-17, whose ex-
pression is not altered in malignant cells. Moreover,
proliferation was increased to 121.7% 	 5.9%, 149.8%
	 16.8%, and 145.0% 	 19.0% of controls (all P 
.05) after 72 hours in cells transfected with miR-141,
miR-21, and miR-200b precursors, respectively, to over
express miRNA expression (Figure 3). We hypothesize
that aberrant expression of selected miRNA can enhance
tumor cell growth.
miRNA as Regulators of Cell Survival In
Vitro
Cholangiocarcinomas are highly chemoresistant
tumors. The aberrant activation of survival signaling in
tumor cells can enhance chemoresistance. Recently,
miR-21 was reported to be an antiapoptotic factor in
human glioblastoma cells, suggesting that aberrantly
expressed certain miRNA may contribute to the malig-
nant phenotype by blocking expression of critical apo-
ptosis-related genes.29 To explore a role for miRNA in
cell survival and the response to chemotherapy, Mz-
ChA-1 cells were transfected with miRNA-speciﬁc anti-
sense inhibitors, and their sensitivity to gemcitabine was
assessed. Anti-miR-21 and anti-miR-200b both in-
creased gemcitabine-induced cytotoxicity by 12.4% and
14.4%, respectively, whereas anti-miR-141 failed to
show a signiﬁcant effect (Figure 4A). Next, we assessed
cell viability in response to gemcitabine in H69 nonma-
lignant cholangiocytes transfected with miRNA precur-
sors. Cell viability was increased by 18.7%, 12.0%, and
14.0% of controls in cells transfected with miR-141,
miR-21, and miR-200b precursors, respectively (Figure
4B). To determine the speciﬁc effect of miRNA on
Table 1. Highly Expressed miRNA in Human Cholangiocyte Cell Lines
H69 Mz-ChA-1 TFK KMCH
miRNA Mean 	 SE miRNA Mean 	 SE miRNA Mean 	 SE miRNA Mean 	 SE
miR21 5.67 	 0.18 miR21 11.42	 0.27 miR21 9.98 	 1.09 let7d 12.90 	 0.63
let7a-1 3.66 	 0.75 let7a-1 3.50 	 0.80 miR16-1 4.42	 0.45 let7a-1 9.57 	 0.58
let7f-2 3.16 	 0.34 let7c 3.05 	 0.61 miR320 4.05	 0.26 let7f-2 9.55 	 0.47
miR290 3.06 	 2.58 miR16-1 2.41 	 0.36 let7a-1 3.79	 0.64 miR21 7.05 	 0.28
let7c 2.84 	 0.46 let7f-2 2.34 	 0.34 miR202 3.44	 0.27 let7c 6.22 	 0.22
miR215 2.75 	 0.26 let7f-2 3.25 	 0.37 miR16-1 5.04 	 0.21
miR202 2.65 	 0.24 let7d 3.04 	 0.31 miR106a 5.02 	 0.33
miR320 2.54 	 0.16 let7c 3.00 	 0.52 miR17-5p 4.78 	 0.62
miR1-2 2.32 	 0.20 let7f-1 4.70 	 0.36
miR16-1 2.03 	 0.23 miR31 3.53 	 0.47
miR24-1 3.46 	 0.35
miR320 2.15 	 0.34
NOTE. For each cell type, miRNA expression is relative to that of a control miRNA, added at a constant amount to the hybridization mix. All miRNA
expressed greater than 2-fold relative to expression of the control miRNA, with a P value of .05, are shown. The H69 cells are nonmalignant,
whereas the Mz-ChA-1, TFK, and KMCH are malignant cholangiocyte cell lines. A group of miRNAs, namely, miR-21, let7a-1, let7 f-2, let 7c,
miR320, and miR16-1, are highly expressed in all cell types and may thus constitute a “cholangiocyte-miRNA cluster.”
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apoptosis, the extent of apoptosis was quantitated during
incubation of Mz-ChA-1 cells with gemcitabine in the
presence or absence of mir-141, miR-200b, or miR-21
inhibitors (Figure 5). Similar to the results of the cell
viability studies, inhibition of miR-21 or miR-200b, but
not miR-141, decreased gemcitabine-induced apoptosis.
These results support a functional role for these miRNA
in mediating cell survival in both malignant and non-
malignant cells and suggest a mechanism by which over
expression of miR-21 and miR-200b miRNA may con-
tribute to chemoresistance in cholangiocarcinoma by
modulating chemotherapy-induced apoptosis.
Chemotherapy Alters miRNA Expression In
Vivo
To evaluate the biologic relevance of alterations in
miRNA expression to chemotherapeutic responses in
vivo, we proﬁled miRNA expression in Mz-ChA-1 tu-
mor cell xenografts in nude mice randomized to treat-
ment with either gemcitabine or control diluent (Figure
6). Gemcitabine treatment resulted in a greater than
2-fold increase in the expression of a group of miRNA
that included miR-202, miR-320, miR-374, miR-1-2,
miR-16-1, miR-24-1, let7f-2, let7a-1, and miR-374
Figure 2. miRNA expression proﬁles in malignant and nonmalignant cholangiocytes. miRNA was isolated and proﬁling performed by miRNA
microarray as described in the Materials and Methods section. miRNA was obtained from normal intrahepatic biliary tract epithelial cells (NBEC);
H69 nonmalignant cholangiocytes; and the human cholangiocarcinoma cell lines Mz-ChA-1, TFK-1, and KMCH-1. A heat map was generated from
the average of normalized log-transformed ﬂuorescent intensity for each data set (n 
 4 separate arrays, each with 2 probes for each miRNA).
The expression relative to the median values is shown with increased relative amounts in red and decreased amounts in green. miRNA are
grouped based on cell type in ascending order of the name list.
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(Table 3). Among these is a group including let7a-1,
let7f-2, and miR-16-1 that are highly expressed in both
nonmalignant and malignant cholangiocytes. Although
the expression of miR202 and miR320 is considerably
decreased in Mz-ChA-1 malignant cholangiocytes when
compared with nonmalignant cholangiocytes, their ex-
pression was highly increased in response to gemcitabine.
Thus, there are dynamic regulatory mechanisms involved
in their decreased expression in tumor cells. Consistent
with their expression in vitro, miR-21, miR-200b, and
miR-141 were all up-regulated in vivo by 2.0- 	 0.1-,
2.3- 	 0.1-, and 1.5- 	 0.1-fold, respectively, when
compared with control miRNA (Figure 6B). Moreover,
expression of miR-21 and miR-200b were further in-
creased by 4.1- 	 0.1- and 1.5- 	 0.1-fold in tumor cell
xenografts treated with gemcitabine compared with con-
trols (Table 3). However, miR-141 expression was de-
creased to 0.6- 	 0.1-fold in tumors treated with gem-
citabine. These results suggest differences between these
miRNA in their mechanisms of regulation of expression
and their functional effects on cell survival in response to
chemotherapeutic stress.
Identiﬁcation of Potential miRNA Targets
for miR-21, miR-200b, and miR-141
There have been several reported efforts to iden-
tify biologically relevant targets of miRNA. To identify
potential targets that may contribute to miRNA regu-
lation of cholangiocarcinoma growth and survival, we
used a bioinformatics approach to identify potential can-
didates for further study using the rules proposed by
Doench and Sharp with slight modiﬁcations.30 The cri-
teria used include 85% complementarity between po-
sitions 2 and 9 of the miRNA and the candidate target
and the overall Tm of the miRNA/mRNA interaction.
This core sequence has been identiﬁed as critical to the
activities of miRNA. Similarly, overall binding stability
between miRNA and mRNA has been shown to be an
Figure 3. Modulation of cholangiocarcinoma cell proliferation by miR-141,
miR-21, andmiR-200b.Mz-ChA-1 cells (5104/well) in 96-well plates were
transfectedwithmiRNA-speciﬁc inhibitors or precursors tomiR-141,miR-21,
or miR-200b or with control precursors or inhibitors. Cell proliferation was
assessed after 72 hours using a viable cell assay and the proliferation index
derived. The mean 	 standard error from 4 separate experiments are
illustrated. *P  .05 when compared with controls.
Table 2. miRNA Differentially Expressed in Malignant Cholangiocytes
Mz-ChA-1 TFK KMCH
miRNA Mean 	 SE miRNA Mean 	 SE miRNA Mean 	 SE
miR200b 7.607 	 0.953 miR141 10.535 	 1.377 miR224 8.531 	 0.154
miR141 5.481 	 0.941 miR181a 5.394 	 0.446 miR220b 7.314 	 0.420
miR34a 4.371 	 0.714 miR181b-1 5.019 	 0.403 miR196a-1 3.986 	 0.405
miR23a 3.020 	 0.121 let7i 4.591 	 0.329 miR92-1 3.066 	 0.073
miR21 2.742 	 0.112 miR21 4.350 	 0.136 miR106a 2.525 	 0.080
miR27a 2.602 	 0.090 miR292-3p 3.951 	 0.361 miR17-5p 2.367 	 0.040
miR222 2.314 	 0.122 miR200b 3.360 	 0.191 miR182 2.281 	 0.067
miR205 2.149 	 0.101 miR23a 2.944 	 0.139 miR328 2.158 	 0.226
miR24-1 2.099 	 0.156 miR23b 2.710 	 0.098 miR200a 2.020 	 0.132
miR215 2.367 	 0.289
miR27a 2.325 	 0.072
miR144 2.287 	 0.228
NOTE. For each malignant cell type, the miRNA expression is represented as a ratio of normalized expression in that cell type relative to the
normalized expression in nonmalignant H69 cells. All miRNA that are expressed in the malignant cells at greater than 2-fold the level of
expression in the nonmalignant cells, and with a P value  .05, are represented in the Table.
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important indicator of miRNA activity. Using these
criteria, we scanned all known mRNA 3=-UTRs as po-
tential targets for miR-21, miR-200b, or miR-141.
Among the predicted mRNA that may be regulated
by miR-141 miRNA is the CLOCK gene, which regu-
lates circadian rhythms. The regulation of CLOCK ex-
pression by miR-141 has been experimentally studied.31
The intracellular circadian clockwork can control the
cell-division cycle directly and unidirectionally in pro-
liferating cells. CLOCK can act as a tumor-suppressor by
regulating the mechanisms by which cells stop dividing
or undergo apoptosis following DNA damage, a response
that may be dependent on the circadian rhythm. Over
expression of mir141 may decrease the expression of
CLOCK. This could contribute to aberrant responses to
DNA damage in cancer cells. Compared with controls,
levels of clock protein were increased in a time-depen-
dent manner after transfection with the speciﬁc miR-141
inhibitor (Figure 7A).
Potential targets for miR-200b were also identiﬁed
using our modiﬁed criteria. For one of the identiﬁed
candidates, the protein tyrosine phosphatase, nonreceptor
type 12 (PTPN12), the putative target sequence was
conserved across species. Protein tyrosine phosphatases
Figure 4. miRNA regulation of gemcitabine-induced cytotoxicity in vitro. Mz-ChA-1 cells, shown in the top panels, were transfected with control
anti-miRNA or miRNA speciﬁc inhibitors to miR-141, miR-21, or miR-200b. H69 nonmalignant cholangiocytes, shown in the bottom panels, were
transfected with miRNA-speciﬁc precursors to miR-141, miR-21, or miR-200b or miRNA precursor control. After 48 hours, cells were incubated
with 30 mol/L gemcitabine or diluent (treatment control) in medium containing 0.5% FBS. Cell viability was assessed after 48 hours, and the
cytotoxicity index was calculated. The cytotoxicity index is the percentage reduction in cell viability in cells incubated with gemcitabine relative
to untreated controls. The results shown represent the mean 	 SE from 4 independent experiments. *P  .05 when compared with control
miRNA precursor or inhibitor group.
Figure 5. miRNA regulation of gemcitabine-induced apoptosis. Mz-ChA-1 cells were transfected with control anti-miRNA or miRNA-speciﬁc
inhibitors to miR-141, miR-21, or miR-200b. After 48 hours, cells were incubated with 30 mol/L gemcitabine or diluent (treatment control) in
medium containing 0.5% FBS. Apoptosis was quantitated after 48 hours by counting the number of cells showing nuclear morphologic changes
of apoptosis after staining with DAPI. The results shown represent the mean 	 SE from 3 separate experiments. *P  .05 when compared with
control miRNA inhibitor group.
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are signaling molecules that have been implicated in
cellular regulation of oncogenic transformation, cell
growth, cell-cycle progression, and cell differentiation.
PTPN12 can bind and dephosphorylate the product of
oncogenes such as c-Abl or Src and inactivate the Ras
pathway.32,33 Thus, deregulation of PTPN12 expression
may contribute to tumor cell survival and oncogenesis.
In cells transfected with anti-miR-200b, PTPN12 ex-
pression was increased to 132.2% 	 7.2% of control
after 48 hours and 147.3% 	 12.8% of control after 72
hours. Moreover, inhibition of miR-200b signiﬁcantly
reduced the tyrosine phosphorylation of a downstream
target Src, a key mediator of tumor cell proliferation and
differentiation (Figure 7B). The altered expression of
miR-200b in malignant cholangiocytes, and in response
to gemcitabine treatment in vivo, may contribute to
oncogenesis by functional deregulation of expression of
key signaling intermediates.
Of the miR-21 targets identiﬁed, we selected the
phosphatase and tensin homolog deleted on chromosome
10 (PTEN) for further study because of the well-charac-
terized role for this gene in tumor biology. PTEN is a
tumor-suppressor gene that, in mutated form, has been
found to be associated with a number of different tu-
mors.34 It encodes a phosphatase that normally inhibits
the survival/growth-promoting activity of the phospho-
inositide 3-kinase (PI-3 kinase)-signaling pathway.35
The PI-3 kinase pathway is constitutively active in many
tumors and mediates a cellular-signaling pathway in-
volved in cell survival. Inhibitors of this prosurvival
network have been shown to sensitize tumor cells to
death stimuli.36 We assessed cellular expression of the
Figure 6. Alterations in miRNA expression in response to gemcitabine in tumor cell xenografts. Mz-ChA-1 cell xenografts were established in nude
mice as described. Once xenograft tumors had formed to a predetermined size, 120 mg/kg gemcitabine or an equivalent volume of diluent
control were administered IP every 3 days for a total of 5 doses. Tumors were then excised, and miRNA were isolated, labeled, and analyzed by
miRNA microarray as described in Materials and Methods section. (A) miRNA expression patterns were analyzed using a self-organizing tree
algorithm using the Multiexperiment Viewer (version 3.1) from the Institute for Genomic Research. A dendrogram showing 3 clusters was
generated. miRNA expression following gemcitabine treatment is shown on the right axis relative to controls on the left axis. Cluster 1 deﬁned
a group of 154 miRNA, which were unchanged or minimally decreased in expression. Cluster 2 included 33 miRNA that showed small increases
in expression, and cluster 3 deﬁned a group of 9 miRNA that had a marked increase following gemcitabine treatment and are listed. (B)
Differential expression of selected miRNA in vivo following treatment with gemcitabine is shown. Data represent fold-change in expression in
gemcitabine treated tumors compared with controls. For each miRNA, the difference between groups was statistically signiﬁcant using Welch
2-sample t test with a P value  .05.
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PTEN in Mz-ChA-1 cells in response to inhibition of
miR-21 using speciﬁc anti-miR 21 inhibitors. The ex-
pression of the PTEN was 2.1- 	 0.3-fold higher in the
miR-21 inhibitor transfected cells after 3 days (Figure
7C). Meanwhile, there was a concomitant reduction of
phosphorylated PI-3 kinase p85 subunit to 0.49- 	
0.02-fold of controls after transfection with the miR-21
inhibitor. Expression of PTEN was unchanged in malig-
nant cholangiocytes treated with an inhibitor targeting
miR-141 (data not shown), which also modulated cell
survival after chemotherapy. Although miR-21 is up-
regulated in malignant cholangiocytes, there is a marked
4-fold increase in expression of miR-21 following
treatment with gemcitabine chemotherapy in vivo.
Moreover, the phosphorylation of PI-3 kinase was sig-
niﬁcantly increased to 160.0% 	 10.4% in xenografts
treated with gemcitabine. In addition, there was a de-
crease in expression of PTEN (Figure 7D). Taken to-
gether, these data are consistent with the hypothesis that
the PTEN is a biologically relevant miR-21 target gene
and indicate that down-regulation of PTEN is not a
general result of inhibition of cell survival.
miR-21 Directly Alters PTEN Expression and
Modulates Gemcitabine-Induced Apoptosis
by Activating PI 3 Kinase-Signaling
Pathways
To assess whether miR-21 can directly alter the
expression of PTEN, we performed luciferase expression
studies using a construct in which a fragment of the
3=-UTR of PTEN mRNA, containing the putative miR-
21-binding sequence was cloned into a ﬁreﬂy luciferase
reporter construct. This construct was cotransfected with
Table 3. Alterations in miRNA Expression in Tumor Xenografts Following Gemcitabine Treatment In Vivo
Expression increased 2-fold Expression decreased 3-fold
miRNA Mean 	 SE P value miRNA Mean 	 SE P value
miR202 5.274 	 0.312 2.65E-09 let7b 0.010 	 0.001 .002
miR320 4.986 	 0.362 1.68-08 miR328 0.097 	 0.001 .013
miR21 4.130 	 0.312 6.06E-08 miR220 0.110 	 0.005 .015
miR374 3.106 	 0.343 5.89E-06 miR197 0.123 	 0.003 .017
miR1-2 2.968 	 0.348 1.21E-05 miR326 0.139 	 0.005 .019
miR16-1 2.735 	 0.311 1.75E-05 miR204 0.142 	 0.002 .020
miR24-1 2.716 	 0.335 3.26E-05 miR346 0.156 	 0.003 .022
let7f-2 2.663 	 0.352 6.02E-05 miR207 0.157 	 0.002 .022
let7a-1 2.601 	 0.362 9.88E-05 miR412 0.157 	 0.003 .022
miR372 2.274 	 0.314 2.68E-04 miR324-3p 0.183 	 0.005 .026
let7c 2.244 	 0.346 5.91E-04 miR211 0.185 	 0.005 .027
let7d 2.199 	 0.337 6.63E-04 miR329 0.186 	 0.010 .027
miR26a-1 2.192 	 0.328 6.00E-04 miR341 0.197 	 0.009 .029
miR217 2.097 	 0.307 7.57E-04 miR345 0.208 	 0.006 .031
miR194-1 2.076 	 0.331 .001 miR337 0.213 	 0.007 .032
miR373* 0.220 	 0.009 .033
miR294 0.224 	 0.005 .034
miR213 0.226 	 0.006 .034
miR324-5p 0.229 	 0.005 .035
miR212 0.229 	 0.004 .035
miR299 0.230 	 0.005 .035
miR149 0.234 	 0.008 .036
miR205 0.246 	 0.005 .038
miR290 0.247 	 0.005 .038
miR133a-1 0.254 	 0.006 .040
miR302c* 0.259 	 0.009 .041
miR199a-2 0.262 	 0.006 .042
miR409 0.266 	 0.006 .043
miR154 0.267 	 0.005 .043
miR342 0.269 	 0.006 .043
miR339 0.280 	 0.006 .046
miR187 0.281 	 0.005 .046
miR186 0.283 	 0.006 .047
miR344 0.283 	 0.005 .047
miR139 0.289 	 0.006 .048
miR128a 0.291 	 0.007 .049
miR291-3p 0.293 	 0.005 .049
miR129-2 0.294 	 0.005 .049
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a control Renilla luciferase reporter construct in Mz-
ChA-1 cells along with control or miR-21-speciﬁc in-
hibitor or precursor miRNA. An increase in relative
luciferase activity was noted with anti-miR-21 and a
corresponding decrease with the miR-21 precursor, in-
dicating that miR-21 can directly modulate gene expres-
sion at the PTEN 3=-UTR (Figure 8A). We next assessed
the potential involvement of PI-3 kinase-dependent
mechanisms in the regulation of cell survival by miR-21.
PTEN is a negative regulator of PI-3 kinase-dependent
signaling. Activation of PI-3 kinase results in the acti-
vation of Akt and downstream mediators involved in cell
survival such as the mammalian target of rapamycin
(mTOR). Introduction of the miR-21 precursor into
Mz-ChA-1 cells decreased PTEN expression (Figure 8B).
Moreover, an increase in basal expression of phosphory-
lated AKT and mTOR was noted in cells transfected
with the miR-21 precursor, which was decreased by
preincubation with 100 mol/L LY294002, a PI-3 ki-
nase inhibitor, or 20 mol/L AKT inhibitor. Further-
more, Mz-ChA-1 cells transfected with the miR-21 pre-
cursor had decreased sensitivity to gemcitabine-induced
apoptosis, but this effect was abrogated in the presence of
either the AKT inhibitor or the mTOR inhibitor rapa-
mycin (Figure 8C). These observations implicate PTEN-
dependent activation of PI-3 kinase and activation of
AKT/mTOR signaling as a mechanism by which in-
creased miR-21 modulates chemosensitivity in cholan-
giocarcinoma cells.
Discussion
Aberrant regulation of gene expression by trans-
lational or posttranslational mechanisms is emerging as
an important contributor to cancer cell growth.37
miRNA are key regulators of mRNA degradation and,
hence, gene expression. Tissue-speciﬁc patterns of
miRNA expression have been reported and postulated to
reﬂect embryologic development. Emerging evidence
implicates alterations in miRNA expression in cancer,
based on the demonstration of an important functional
role of miRNA such as let-7a in development.38 Aber-
rant miRNA expression proﬁles have been recently re-
ported in cancer cells compared with normal cells and
have been postulated to reﬂect embryologic develop-
ment.5 Although these deviant patterns of miRNA ex-
Figure 7. Inhibition of miRNA modulates expression of miRNA targets. Mz-ChA-1 cells were transfected with 30 nmol/L antisense inhibitor
targeting miR-21, miR-200b, or miR-141. Cell lysates were obtained at baseline and after 48 and 72 hours for immunoblot analysis of protein
expression of predicted target proteins for (A) miR-141 (CLOCK); (B) miR-200b (PTPN12 and its downstream target Src); and (C) miR-21 (PTEN
and its downstream target PI-3K p85 subunit). The blots were stripped and reprobed for -tubulin as a loading control and for quantitation.
Representative immunoblots are shown along with quantitative data that show the mean 	 standard error from 4 separate blots. *P  .05
relative to baseline value. (D) miR-21 expression is increased in vivo following gemcitabine treatment. To assess the effect of increased miR-21
on potential downstream targets, immunoblots for PTEN, phosphorylated PI-3 kinase p85 subunit, and -tubulin were performed in the
homogenates from tumor cell xenografts following treatment with gemcitabine or diluent control. A decrease in expression of PTEN, the miR-21
predicted target, along with increased phosphorylation of p85 was observed in vivo. Representative immunoblots are shown along with
quantitative data from 3 separate experiments. *P  .05 relative to control.
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Figure 8. miR-21 regulates PTEN expression and PI 3-kinase signaling. (A) Mz-ChA-1 cells were plated (2  106 cells/well) in 6-well plates. One
microgram of the pGL3-PTEN-3=-UTR ﬁreﬂy luciferase expression construct and 1 g of a Renilla luciferase expression construct pRL-TK (Promega)
were cotransfected with the miR-21 or control precursor or inhibitor. Luciferase assays were performed 48 hours after transfection using the dual
Luciferase Reporter Assay System (Promega, Madison, WI). Fireﬂy luciferase activity was normalized to Renilla luciferase activity for each sample.
The results represent the mean and standard deviation of 8 separate determinations. (B) Mz-ChA-1 cells were transfected with 30 nmol/L miR-21
precursor miRNA or control miRNA. After 48 hours, media was replaced with CMRL medium containing 0.5% FBS and either 100 mol/L
LY294002, a PI 3-kinase speciﬁc inhibitor, or 20 mol/L 1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (Akt inhibitor).
Cell lysates were obtained after 24 hours for immunoblot analysis of PTEN, phospho-Akt Ser(P)473, and phospho-mTOR Ser(P)248. The blots were
stripped and reprobed for -tubulin as a loading control and for quantitation. Representative immunoblots are shown along with quantitative data
that show the mean 	 standard error from 4 separate blots. *P  .05 relative to expression in the presence of miR-21 precursor. **P  .05
relative to expression in the presence of control precursor. (C) miR-21-dependent inhibition of gemcitabine-induced apoptosis is decreased by
either the Akt inhibitor or the mTOR inhibitor rapamycin. Mz-ChA-1 cells were transfected with miR-21 or control precursor in CMRL medium with
10% FBS. After 48 hours, the medium was replaced with CMRL medium containing 0.5% FBS and 100 mol/L gemcitabine, with or without 20
mol/L Akt inhibitor, or 100 nmol/L rapamycin. Apoptosis was quantitated by DAPI staining after 48 hours. The results shown represent the
mean 	 SE from 3 separate experiments. *P  .05 relative to control precursor group.
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pression may contribute to malignant transformation,
the central role of miRNA in the regulation of gene
expression indicates that aberrant miRNA expression
may also determine transformed cell behavior. miRNA
are likely to have a broad targeting ability because only
a small number of nucleotide bases are needed to target
mRNA. Thus, changes in expression of even a single
miRNA can have a signiﬁcant impact and result in
diverse cellular effects by “re-programming” gene expres-
sion. The identiﬁcation of alterations in miRNA expres-
sion in malignant cells in a tissue-speciﬁc manner is
therefore likely to be essential to understand the mech-
anisms and role of altered gene expression in cancer.
Thus, we sought to identify aberrantly expressed
miRNA in malignant cells and to begin to deﬁne their
potential relevance to tumor cell growth or chemother-
apeutic resistance.
Our studies identify several miRNA that are con-
sistently altered in expression in malignant cholangio-
cytes. It should be noted that these data were derived
from cholangiocarcinoma cell lines, which may have a
different proﬁle from primary tumors. Thus, future
studies to assess variations in miRNA proﬁles in pri-
mary tumors are warranted. Such studies should in-
clude analysis of an adequate number of samples,
matched as far as possible for prior exposure to che-
motherapy. Although we have focused our studies on
miRNA that are differentially up-regulated in cancer
cells, it is equally likely that down-regulated miRNA
may also contribute to tumor cell behavior. However,
we have observed a decrease in expression of several
miRNA in all malignant cells. These observations are
consistent with the identiﬁed role of miRNA in nor-
mal cellular differentiation and development and may
potentially reﬂect a loss of cellular differentiation.
These observations are similar to those made recently
in other cancer cell types. Moreover, our ﬁndings add
to the emerging body of evidence suggesting tissue-
speciﬁc expression of miRNA. A cluster of miRNA is
highly expressed in epithelial tumors originating from
colon, pancreas, liver, and stomach (miR-192, miR-
194, miR-215) and is thought to reﬂect a common
developmental origin.5 However, this cluster was not
over-expressed in cholangiocarcinoma. Thus, cholan-
giocarcinoma-associated miRNA that are differen-
tially up-regulated may play functional tissue-speciﬁc
roles rather than recapitulate developmental origin.
There are important clinical implications of our
observations. A group of miRNA, namely, miR-21,
let7a-1, let7 f-2, let 7c, miR-320, and miR-16-1, are
highly expressed in human cholangiocytes. Expression
of these miRNA varies from that reported for hepa-
tocytes. This group of miRNA, therefore, represents a
“cholangiocyte-miRNA cluster,” which may be help-
ful for developmental or cell type-speciﬁc cellular
responses. miR-122 is highly overexpressed in the
liver and has been implicated in the replication of
hepatitis C virus replication.39 However, expression of
miR-122 in cholangiocytes is much lower. It is tempt-
ing to speculate that these differences may account for
cell type-speciﬁc differences in viral persistence be-
tween hepatocytes and cholangiocytes. Other miRNA
such as let-7i may contribute to cholangiocyte-speciﬁc
responses to environmental pathogens such as Crypto-
sporidium parvum.
Techniques to isolate and amplify miRNA and to
perform global miRNA expression proﬁling are rapidly
advancing, making it likely that miRNA proﬁling in
clinical tissues will become feasible.5,40–42 The diagnosis
of cholangiocarcinoma is often difﬁcult because of histo-
logic similarities with metastatic tumors from other
primary epithelial tumors. Moreover, the diagnosis of
malignancy in biliary tract strictures remains a perplex-
ing clinical challenge because of the limitations of cyto-
logic techniques to distinguish cancer cells. Assays based
on proﬁling cancer-associated changes in miRNA expres-
sion or selective assays using highly over expressed
miRNA may be potentially useful to diagnose cholan-
giocarcinoma. Thus, further studies to analyze the pat-
terns of miRNA expression in human cholangiocarci-
noma are warranted.
The mechanisms by which miRNA expression is al-
tered in cholangiocarcinoma, or in other cancers, is a
subject of considerable interest. Other than for miR-141,
miRNA chromosomal sites were not associated with
regions of chromosomal loss in biliary tract cancers.
Because of the small size of miRNA genes, it is never-
theless possible that genetic abnormalities such as loss of
heterozygosity or mutations may account for differential
expression in tumor cells. Other mechanisms may in-
clude dysregulated expression by transcription factors
such as c-Myc, which has been shown to modulate the
expression of a cluster of miRNA.21 Because miRNA are
developmental regulators, differential expression of
miRNA may reﬂect the effect of biliary tract differenti-
ation factors.
Of the cholangiocarcinoma-associated miRNA, miR-
141 appears to be an important regulator of tumor cell
proliferation in vitro but does not appear to be involved
in tumor cell responses to chemotherapeutic stress. Strat-
egies to decrease miR-141 overexpression may be poten-
tially useful to limit tumor growth, especially for tumors
associated with regions of chromosomal gain involving
the genomic location of miR-141. In addition, identiﬁ-
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cation of speciﬁc miR-141 gene targets involved in tu-
mor cell proliferation may provide much needed insights
into the mechanisms of growth regulation in cholangio-
carcinoma.
Chemotherapeutic stress results in altered expression
of a surprising number of diverse miRNA. These include
miRNA such as miR-21 and miR-200b that are over-
expressed in malignant cells and miRNA such as miR-
145, miR-23a, and miR-34c that are not differentially
expressed in cancer cells. We speculate that the former
group of miRNA may be involved in survival responses
that are altered in malignant cells, whereas the latter may
reﬂect the general cellular response to death-inducing
stimuli. However, detailed further evaluation will be
necessary to assess whether or not an individual miRNA
reﬂects a cause or a consequence of exposure to chemo-
therapy. miR-21 is overexpressed in many cancers and
has been implicated as having a role in inhibiting apo-
ptosis.29 Increased miR-21 expression following exposure
to cytotoxic drugs suggests that miR-21 may mediate a
general response to adverse conditions that would pro-
mote cell death and supports a central role for this
miRNA in malignant transformation. Characterization
of miR-21-regulated survival mechanisms may eventu-
ally lead to improved therapeutic strategies. Although
we have identiﬁed some potential targets of miR-21 and
miR-200b, several others may exist, and their interac-
tions will need to be studied. Because of the promiscuity
of mRNA targets for individual miRNA, the cellular
responses to chemotherapeutic stress in this experimental
framework may be more complex than previously appre-
ciated.
The modulation of aberrantly expressed miRNA may
be a useful strategy to limit tumor cell proliferation or
improve responses to cytotoxic therapies. Further work
based on selected targets identiﬁed by our studies needs
to be done to evaluate their efﬁcacy in tumor models in
vivo and to develop subsequently the miRNA targeting
therapeutic strategies. Furthermore, the identiﬁcation of
speciﬁc miRNA gene targets that are involved in tumor
cell behavior, such as CLOCK, PTEN, and PTPN12;
elucidation of the mechanisms by which they are regu-
lated; and their functional effects will provide potential
targets to reduce chemoresistance and tumor growth.
Knowledge of speciﬁc processes that are regulated in a
miRNA manner and identiﬁcation of critical targets for
individual miRNA will yield useful information and
novel insights into the mechanisms of tumorigenesis and
chemoresistance in cholangiocarcinoma and other can-
cers.
References
1. Ambros V, Lee RC. Identiﬁcation of microRNAs and other tiny
noncoding RNAs by cDNA cloning. Methods Mol Biol 2004;265:
131–158.
2. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD,
Shimizu M, Cimmino A, Zupo S, Dono M, Dell’Aquila ML, Alder H,
Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. MicroRNA
proﬁling reveals distinct signatures in B-cell chronic lymphocytic
leukemias. Proc Natl Acad Sci U S A 2004;101:11755–11760.
3. McManus MT. MicroRNAs and cancer. Semin Cancer Biol 2003;
13:253–258.
4. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri
S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human
microRNA genes are frequently located at fragile sites and
genomic regions involved in cancers. Proc Natl Acad Sci U S A
2004;101:2999–3004.
5. Lu J, Getz G, Miska EA, Varez-Saavedra E, Lamb J, Peck D,
Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR,
Jacks T, Horvitz HR, Golub TR. MicroRNA expression proﬁles
classify human cancers. Nature 2005;435:834–838.
6. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepa-
tol 2006;3:33–42.
7. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology
2005;128:1655–1667.
8. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Chol-
angiocarcinoma. Lancet 2005;366:1303–1314.
9. Patel T. Increasing incidence and mortality of primary intrahepatic
cholangiocarcinoma in the United States. Hepatology 2001;33:
1353–1357.
10. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Har-
greaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in
mortality rates from intrahepatic cholangiocarcinoma in England
and Wales 1968-1998. Gut 2001;48:816–820.
11. Patel T. Worldwide trends in mortality from biliary tract malignan-
cies. BMC Cancer 2002;2:10.
12. Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholan-
giocyte proliferation via an interleukin-6-mediated activation of
p44/p42 mitogen-activated protein kinase. Hepatology 1999;
29:1037–1043.
13. Tadlock L, Yamagiwa Y, Marienfeld C, Patel T. Double-stranded
RNA activates a p38 MAPK-dependent cell survival program in
biliary epithelia. Am J Physiol Gastrointest Liver Physiol 2003;
284:G924–G932.
14. Yamagiwa Y, Marienfeld C, Tadlock L, Patel T. Translational regula-
tion by p38mitogen-activated protein kinase signaling during human
cholangiocarcinoma growth. Hepatology 2003;38:158–166.
15. Grubman SA, Perrone RD, Lee DW, Murray SL, Rogers LC,
Wolkoff LI, Mulberg AE, Cherington V, Jefferson DM. Regulation of
intracellular pH by immortalized human intrahepatic biliary epi-
thelial cell lines. Am J Physiol 1994;266:G1060–G1070.
16. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted
J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snufﬁn M, Rezant-
sev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z,
Vinsavich A, Trush V, Quackenbush J. TM4: a free, open-source
system for microarray data management and analysis. Biotech-
niques 2003;34:374–378.
17. Schmittgen TD, Jiang J, Liu Q, Yang L. A high-throughput method
to monitor the expression of microRNA precursors. Nucleic Acids
Res 2004;32:e43.
18. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression
proﬁling of microRNA precursors in human cancer cell lines.
Nucleic Acids Res 2005;33:5394–5403.
19. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of
tiny RNAs with probable regulatory roles in Caenorhabditis el-
egans. Science 2001;294:858–862.
2128 MENG ET AL GASTROENTEROLOGY Vol. 130, No. 7
20. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin
6-mediated mitogen-activated protein kinase activation attenu-
ates growth of a cholangiocarcinoma cell line. Hepatology 1999;
30:1128–1133.
21. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 2005;
435:839–843.
22. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D,
Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ,
Hammond SM. A microRNA polycistron as a potential human
oncogene. Nature 2005;435:828–833.
23. Michael MZ, O’Connor SM, Holst Pellekaan NG, Young GP, James
RJ. Reduced accumulation of speciﬁc microRNAs in colorectal
neoplasia. Mol Cancer Res 2003;1:882–891.
24. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler
H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M,
Bullrich F, Croce CM. Frequent deletions and down-regulation of
micro-RNA genes miR15 and miR16 at 13q14 in chronic lympho-
cytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524–
15529.
25. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High
expression of precursor microRNA-155/BIC RNA in children with
Burkitt lymphoma. Genes Chromosomes Cancer 2004;39:167–
169.
26. Baudis M, Cleary ML. Progenetix.net: an online repository for
molecular cytogenetic aberration data. Bioinformatics 2001;17:
1228–1229.
27. Baudis M. Progenetix cytogenetic online database. www.progenetix.
net. Accessed May 27, 2005.
28. Chariyalertsak S, Khuhaprema T, Bhudisawasdi V, Sripa B,
Wongkham S, Petmitr S. Novel DNA ampliﬁcation on chromo-
somes 2p25.3 and 7q11.23 in cholangiocarcinoma identiﬁed by
arbitrarily primed polymerase chain reaction. J Cancer Res Clin
Oncol 2005;1–8.
29. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapo-
ptotic factor in human glioblastoma cells. Cancer Res 2005;65:
6029–6033.
30. Doench JG, Sharp PA. Speciﬁcity of microRNA target selection in
translational repression. Genes Dev 2004;18:504–511.
31. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C,
Mourelatos Z, Hatzigeorgiou A. A combined computational-exper-
imental approach predicts human microRNA targets. Genes Dev
2004;18:1165–1178.
32. Davidson D, Veillette A. PTP-PEST, a scaffold protein tyrosine
phosphatase, negatively regulates lymphocyte activation by tar-
geting a unique set of substrates. EMBO J 2001;20:3414–
3426.
33. Cong F, Spencer S, Cote JF, Wu Y, Tremblay ML, Lasky LA, Goff
SP. Cytoskeletal protein PSTPIP1 directs the PEST-type protein
tyrosine phosphatase to the c-Abl kinase to mediate Abl dephos-
phorylation. Mol Cell 2000;6:1413–1423.
34. Di CA, Pandolﬁ PP. The multiple roles of PTEN in tumor suppres-
sion. Cell 2000;100:387–390.
35. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol
3=-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-
related apoptosis-inducing ligand-induced apoptosis in non-small
cell lung cancer cells. Cancer Res 2002;62:4929–4937.
36. Lee JT Jr, Steelman LS, McCubrey JA. Phosphatidylinositol 3’-
kinase activation leads to multidrug resistance protein-1 expres-
sion and subsequent chemoresistance in advanced prostate
cancer cells. Cancer Res 2004;64:8397–8404.
37. Chen PY, Meister G. microRNA-guided posttranscriptional gene
regulation. Biol Chem 2005;386:1205–1218.
38. Chen CZ. MicroRNAs as oncogenes and tumor suppressors.
N Engl J Med 2005;353:1768–1771.
39. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modula-
tion of hepatitis C virus RNA abundance by a liver-speciﬁc mi-
croRNA. Science 2005;309:1577–1581.
40. Liang RQ, Li W, Li Y, Tan CY, Li JX, Jin YX, Ruan KC. An oligonu-
cleotide microarray for microRNA expression analysis based on
labeling RNA with quantum dot and nanogold probe. Nucleic
Acids Res 2005;33:e17.
41. Esquela-Kerscher A, Slack FJ. The age of high-throughput mi-
croRNA proﬁling. Nat Methods 2004;1:106–107.
42. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M,
Dumitru CD, Shimizu M, Zupo S, Dono M, Alder H, Bullrich F,
Negrini M, Croce CM. An oligonucleotide microchip for genome-
wide microRNA proﬁling in human and mouse tissues. Proc Natl
Acad Sci U S A 2004;101:9740–9744.
Received October 10, 2005. Accepted February 15, 2006.
Address requests for reprints to: Tushar Patel, MBChB, Scott and
White Clinic, Texas A&M University Health Science Center, 2401 South
31st St, Temple, Texas 76508. e-mail: tpatel@swmail.sw.org; fax:
(254) 724 8276 or (254) 742 7181.
Supported by the Scott and White Hospital Foundation and grant
DK069370 from the National Institutes of Health.
The authors thank Dr Robert Jamroz and Usha Chowdhury of the
Microarray Core Facility in the Department of Medical Physiology,
Texas A&M University System Health Science Center for their excellent
technical service in micro-RNA array preparation, hybridization, and
analysis.
June 2006 miRNA EXPRESSION IN CHOLANGIOCARCINOMA 2129
